Global ophthalmic footprint Sentiss operates across India, USA, Europe, Dubai, Russia and Central Asia with capabilities in R&D and multiple manufacturing facilities, presenting sales opportunities in generic and innovative eye care products across regions with established distribution and partner networks.

Acquisition leverage With the Akorn AG acquisition adding a US FDA approved sterile ophthalmic manufacturing facility, there is potential to expand contract manufacturing, licensing, and co-development deals for sterile eye drops and ointments in North American and global markets.

CSR and workplace credibility Awarded for CSR practices and Great Place to Work certification reinforce Sentiss as a reputable partner, easing engagement with healthcare providers, distributors, and contract manufacturing partners seeking responsible and reliable collaborators.

Scale and capacity Large scale operations and a workforce spanning 501-1000 direct employees with extensive external partnerships indicate capacity for volume supply, long-term contracts, and rapid onboarding of new sterile ophthalmic products.

Strategic partnerships Active in contract manufacturing, in-licensing and out-licensing across global markets creates sales opportunities for co-development, market entry alliances, and portfolio expansion through Sentiss’s eye care specialty platform.